Fiera Capital (Canada)
TVTX icon

Fiera Capital (Canada)’s Travere Therapeutics TVTX Stock Holding History

Fiera Capital (Canada)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.4M Sell
516,997
-383,871
-43% -$17M 0.11% 137
2026
Q1 		$26.8M Buy
900,868
+26,815
+3% +$802K 0.09% 166
2025
Q4 		$33.4M Buy
+874,053
New +$28.4M 0.11% 150

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiera Capital (Canada)'s TVTX Position: Q2 2026 in Review

Fiera Capital (Canada) reduced its Travere Therapeutics (TVTX) stake by 43% in Q2 2026, selling an estimated $17M and leaving 516,997 shares worth $29.4M. The position accounts for 0.11% of the portfolio, ranked #137.

Fiera Capital (Canada) first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $33.4M in Q4 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Fiera Capital (Canada) held 516,997 shares of Travere Therapeutics worth $29.4M as of Q2 2026.
  • Fiera Capital (Canada) sold 383,871 Travere Therapeutics shares in Q2 2026, an estimated $17M.
  • Travere Therapeutics made up 0.11% of Fiera Capital (Canada)'s portfolio in Q2 2026, its #137 holding.
  • Fiera Capital (Canada) first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Fiera Capital (Canada)'s Travere Therapeutics position peaked at $33.4M in Q4 2025.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Fiera Capital (Canada)'s 13F filing for Q2 2026, filed 7 Aug 2026.